SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

被引：15

作者：

Fizazi, Karim ^{[1
]}

Miller, Kurt ^{[2
]}

机构：

[1] Univ Paris 11, Inst Gustave Roussy, F-94805 Villejuif, France

[2] Univ Med Berlin, Charite, Berlin, Germany

来源：

BJU INTERNATIONAL | 2009年 / 104卷 / 10期

关键词：

CONTROLLED-TRIAL; END-POINTS; ATRASENTAN; DOCETAXEL; CHEMOTHERAPY; PHASE-3; MEN;

D O I：

10.1111/j.1464-410X.2009.08740.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1423 / 1425

页数：3

共 15 条

[1] Endothelin receptors as novel targets in tumor therapy [J].

Bagnato A. ;

Natali P.G. .

Journal of Translational Medicine, 2 (1)

[2] The hazards of intermediate endpoints [J].

Beer, Tomasz M. ;

Ryan, Christopher W. .

CANCER, 2007, 110 (09) :1877-1879

[3] Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].

Carducci, MA ;

Padley, RJ ;

Breul, J ;

Vogelzang, NJ ;

Zonnenberg, BA ;

Daliani, DD ;

Schulman, CC ;

Nabulsi, AA ;

Humerickhouse, RA ;

Weinberg, MA ;

Schmitt, JL ;

Nelson, JB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689

[4] A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer [J].

Carducci, Michael A. ;

Saad, Fred ;

Abrahamsson, Per-Anders ;

Dearnaley, David R. ;

Schulman, Claude C. ;

North, Scott A. ;

Sleep, Darryl J. ;

Isaacson, Jeffrey D. ;

Nelson, Joel B. .

CANCER, 2007, 110 (09) :1959-1966

[5] Targeted Therapy in Prostate Cancer-Are We Our Own Worst Enemy? [J].

Dowson, Nancy A. .

CANCER, 2008, 113 (09) :2376-2378

[6] Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data [J].

Fizazi, Karim ;

Le Maitre, Aurelie ;

Hudes, Gary ;

Berry, William R. ;

Kelly, W. Kevin ;

Eymord, Jean-Christophe ;

Logothetis, Christopher J. ;

Pignon, Jean-Pierre ;

Michiels, Stefan .

LANCET ONCOLOGY, 2007, 8 (11) :994-1000

[7] Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 [J].

Growcott, James W. .

ANTI-CANCER DRUGS, 2009, 20 (02) :83-88

[8] Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer [J].

Italiano, Antoine ;

Ortholan, Cecile ;

Oudard, Stephane ;

Pouessel, Damien ;

Gravis, Gwenaelle ;

Beuzeboc, Philippe ;

Bompas, Emmanuelle ;

Flechon, Aude ;

Joly, Florence ;

Ferrero, Jean-Marc ;

Fizazi, Karim .

EUROPEAN UROLOGY, 2009, 55 (06) :1368-1376

[9] Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial [J].

James, Nicholas D. ;

Caty, Armelle ;

Borre, Michael ;

Zonnenberg, Bernard A. ;

Beuzeboc, Philippe ;

Morris, Thomas ;

Phung, De ;

Dawson, Nancy A. .

EUROPEAN UROLOGY, 2009, 55 (05) :1112-1123

[10] The endothelin axis: Emerging role in cancer [J].

Nelson, J ;

Bagnato, A ;

Battistini, B ;

Nisen, P .

NATURE REVIEWS CANCER, 2003, 3 (02) :110-116

← 1 2 →